Cannformatics-HeroBanner-01 (16).png

Personalizing Medical Cannabis Treatment 

A NEW APPROACH

WATCH HOW WE ARE PERSONALIZING MEDICAL CANNABIS TREATMENT
shutterstock_429937732 [Converted]-04.pn
SCIENCE-BASED EVALUATION

Our proprietary technology measures metabolic biomarkers to quantify how each person responds to cannabis, accounting for the genetic makeup, environmental and lifestyle factors of each individual.

PERSONALIZED TREATMENT

Our bioinformatics platform guides you to the best-fit available medical cannabis treatment, optimizing products, dosage and consumption methods to meet your wellness needs and improve quality of life.

shutterstock_429937732 [Converted]-03.pn
shutterstock_429937732 [Converted]-02.pn
AREA OF FOCUS

Initially we are focusing on Autism, with plans to expand to anxiety, pain, neurodegenerative diseases and nausea. Our platform is designed to work for virtually any medical condition treatable by cannabis.

FB Profile_edited.png

OUR MISSION

To deliver predictable and repeatable science-based medical cannabis outcomes to improve health and quality of life.

 NEW STANDARDS FOR MEDICAL CANNABIS TREATMENT

Our Commitment

We are committed to being an unbiased partner to the medical cannabis community, providing medical and scientific data to improve wellness outcomes, reduce stigma and inspire innovation across the industry.

Health Care Providers (HCP)

We partner with HCPs who recommend cannabis to their patients. Our bioinformatics platform will help HCPs understand the impact of medical cannabis treatment on each individual. If you would like to know more, please contact us.

Confidential

The privacy  and  confidentiality of your personal and medical information is important to us. Cannformatics is HIPAA-compliant. We comply with all Federal, State and local privacy and security regulations.

Cannformatics does not diagnose medical conditions, prescribe medical cannabis or recommend cannabis as a replacement for medical treatment.

shutterstock_602534855 1 (1).png

SCIENCE &
APPLICATION

"Cannabis-Responsive biomarkers: A pharmacometabolomics-based application to evaluate the impact of medical cannabis treatment on children with ASD" 

shutterstock_1400143325 1 (1).png

AUTISM SPECTRUM DISORDER PILOT

“One of our primary goals was to scientifically validate Cannabis-Responsive biomarkers as a universal measurement for evaluating cannabis impact..."

shutterstock_51805276 1 (1).png

CANNFORMATICS
IN THE NEWS

Check out articles, podcasts and blog posts about the ASD Pilot Study and Cannabis-Responsive™ biomarkers.

_MG_0122-Edit%20(1)_edited.jpg
2020-06-11_outsidejacket_edited_edited.jpg
Robert-McKee.jpg

OUR TEAM

We have decades of experience, with over 120 published scientific papers and patent applications an extensive background in founding, R&D, protecting IP & Data Privacy in biotech and  Pharma and marketing & branding in the cannabis industry.